Latest filing published 04 Mar 2022 for Aurinia Pharmaceuticals Inc..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Neil Solomons: trading record in brief
Neil Solomons, listed as senior executive, appears in our data through filings on Aurinia Pharmaceuticals Inc. shares, published by SEC (Form 4). Between 12 March 2021 and 2 March 2022, the trades on record add up to 17 filings.
No open-market purchase appears, only 10 sales worth €11.4M. Outside the open market, there are 1 share grant and 6 option exercises. So far in 2022, the count stands at no purchases and 1 sale.
On 4 March 2022 came the latest disclosure, an open-market sale for €52k in Aurinia Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Neil Solomons
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 8,500 shares0Common StockSEC:0001628280-22-005119:0
- 50,000 shares@ US$30.1750.1% of flowCommon SharesSEC:0001628280-21-023153:0
- 45,000 shares@ US$5.307.9% of flowCommon StockSEC:0001628280-21-021484:0
- 150,000 shares@ US$3.2015.7% of flowCommon SharesSEC:0001628280-21-018594:0
- 5,000 shares@ US$15.852.6% of flowCommon StockSEC:0001628280-21-017662:0
- 45,000 shares@ US$16.0323.7% of flowCommon StockSEC:0001628280-21-016407:0
6 of 6 declarations
